United States Of America- 29-01-2026

The global bioproduction market is witnessing a transformative growth phase as advances in automation, rising biosimilar adoption, and expanding biologics pipelines reshape the biomanufacturing landscape. According to industry analysis, the bioproduction market size is projected to grow from US$ 22,337.24 million in 2022 to US$ 63,393.93 million by 2030, registering a robust compound annual growth rate of 13.9% during 2022–2030. This strong growth trajectory highlights the increasing strategic importance of scalable, efficient, and compliant manufacturing solutions for biologics and advanced therapies.
Bioproduction refers to the large-scale manufacturing of biologics, biosimilars, vaccines, cell and gene therapies, and nucleic acid therapeutics using living cells and biological systems. It forms the backbone of modern biopharmaceutical development, enabling the commercialization of complex therapies for cancer, autoimmune diseases, metabolic disorders, and rare genetic conditions. As healthcare systems worldwide increasingly rely on biologics for targeted and personalized treatment, the demand for advanced bioproduction capabilities continues to accelerate.
One of the most significant forces driving market growth is the rapid adoption of automation in biomanufacturing. Automation delivers multiple benefits to manufacturers, including reduced contamination risk, improved process consistency, lower operational costs, and enhanced regulatory compliance. Automated and closed systems are particularly valuable for complex therapies such as CAR-T cell therapies, where process variability and manual intervention can significantly impact product quality. As cell therapies evolve from academic research to commercial-scale production, manufacturers are prioritizing integrated platforms that combine upstream and downstream operations within controlled environments.
Digitalization is also playing a crucial role in reshaping bioproduction workflows. GMP-compliant software platforms that support data traceability, real-time monitoring, and process optimization are increasingly being adopted across academic institutions, biotechnology firms, and contract manufacturing organizations. These digital tools help streamline development timelines, support regulatory submissions, and enable manufacturers to scale production efficiently without compromising quality standards.
Another major growth catalyst for the bioproduction market is the rising demand for biosimilars. Patent expirations of several blockbuster biologics are creating lucrative opportunities for biosimilar manufacturers worldwide. As biosimilars offer cost-effective alternatives to originator biologics, their adoption is expanding rapidly across oncology, autoimmune diseases, diabetes, and other chronic conditions. This trend is driving increased investments in bioproduction infrastructure, including bioreactors, consumables, and downstream processing equipment, to support higher production volumes and competitive pricing strategies.
From a segmentation perspective, biologics and biosimilars currently account for the largest share of the bioproduction market due to their established commercial demand. However, the cell and gene therapies segment is expected to register the fastest growth rate through 2030, supported by expanding clinical pipelines and increasing regulatory approvals. By application, the cancer segment dominates the market, reflecting the critical role of biologics and biosimilars in oncology treatment and supportive care. In terms of equipment, consumables and accessories represent a significant revenue contributor, driven by recurring demand and the growing adoption of single-use technologies.

Get More Information On:- https://www.theinsightpartners.com/sample/TIPRE00020213

Regionally, North America holds the largest share of the global bioproduction market, supported by advanced research infrastructure, strong regulatory frameworks, and high adoption of biologics and biosimilars. Meanwhile, Asia Pacific is expected to register the highest growth rate during the forecast period. This growth is attributed to increasing investments in biopharmaceutical manufacturing, expanding healthcare infrastructure, supportive government initiatives, and a growing focus on research and development across emerging economies.
The competitive landscape of the bioproduction market is characterized by continuous innovation, strategic collaborations, and capacity expansion initiatives. Leading players such as Thermo Fisher Scientific Inc, Merck KGaA, Lonza Group AG, Sartorius AG, Danaher Corp, FUJIFILM Irvine Scientific Inc, Bio-Rad Laboratories Inc, bbi-biotech GmbH, and F. Hoffmann-La Roche Ltd are actively investing in advanced technologies, automation platforms, and global expansion strategies to strengthen their market positions.
Looking ahead, the bioproduction market is expected to maintain strong momentum through 2030 as automation, digital integration, and biosimilar demand continue to reshape global biomanufacturing. Companies that invest in scalable infrastructure, flexible production systems, and end-to-end solutions are well positioned to capitalize on the growing demand for high-quality biologics and advanced therapies. As healthcare systems increasingly prioritize innovation, affordability, and efficiency, bioproduction will remain a critical enabler of next-generation medical treatments worldwide.

About The Insight Partners
The Insight Partners is a one-stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Devices, Technology, Media and Telecommunications, and Chemicals and Materials.

Contact Us
Email: [email protected]
Website: www.theinsightpartners.com
Phone: +1-646-491-9876

Related Report:- https://www.theinsightpartners.com/reports/transport-media-market